9127184

KFW/	
10 10	

2 1 200k 30'1	Under the Paperwork Reduction Act of 1995, no	p persons are required			PTO/SB/21 (08-03) arough 07/31/2006. OMB 0651-0031 S. DEPARTMENT OF COMMERCE isplays a valid OMB control number.
Ta TRADERE	/ TRANSMITT.	TRANSMITTAL			04
	FORM (to be used for all correspondence after	r initial filing)	First Named Inventor Art Unit	Joshua .	D. Rabinowitz
			Examiner Name	To be as	
U	Total Number of Pages in This Submission		Attorney Docket Number	00023.0	3CON
	····	ENCLOS	URES (check all that app	ıly)	
	Fee Transmittal Form	Drawing(s)	Afte to 0	er Allowance communication Group peal Communication to Board
	Fee Attached Amendment / Reply	Licensing	g-related Papers	of Apr	Appeals and Interferences peal Communication to Group peal Notice, Brief, Reply Brief)
	After Final	Provision	o Convert a nal Application		oprietary Information
	Affidavits/declaration(s)	Change of	Attorney, Revocation of Correspondence		atus Letter ther Enclosure(s) <i>(please</i>
	Extension of Time Request		Disclaimer	ide	entify below):
	Express Abandonment Request Information Disclosure Statement		for Refund nber of CD(s)		
	Certified Copy of Priority Document(s)	Remarks			
	Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Info. Discl. State Form 1449 (3 co Copy of <u>krefo</u> Return postcard	pies , 7 pages each) erences_ 164		
	SIGNATUI	RE OF APPLICA	NT, ATTORNEY, OR AGE	NT	
or	ALEXZA MDC, 100 Elaine C Stracker, Pl	1 East Meadow C h.D., J.D. Telep	Circle, Palo Alto, CA 94303 Ohone (650)-687-3905	Custom	ner Number 37485
Si	gnature Hum	O Street			
Da	SEP. 24	2004			
	CE	RTIFICATE O	F TRANSMISSION/MA	LING	
 	ereby certify that this correspondence is be	ing facsimile transn	nitted to the USPTO or deposit	ed with the Un	ited States Postal Service with Alexandria,VA 22313-1450 on th
suff	ildent postage as first dass mair in an env	0.000			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR

AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

.

PATENT

Attorney's Docket No.: 00023.03CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/813,722

Filed:

3/31/2004

Title

DELIVERY OF MUSCLE RELAXANTS THROUGH AN

INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

1

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date:

SEP. 24 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

Form PTO-1449	Docket Number:	0023.03CON	Application Numb	Application Number: 10/813,722	
TORMATION DISCLOSURE CITATION AN APPLICATION SEP 2 4 2004 (Use several sheets if necessary)	Applicant:	Joshua D. RA	BINOWITZ et al.		
	Filing Date:	3/31/2004	Group Art Unit:	Not Yet Known	
TRADEMARK			٠		

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	10/19/1976	3,987,052	Hester, Jr.			
	3.	05/27/1980	Re. 30,285	Babington			
	4.	01/23/1990	4,895,719	Radhakrishnun et al.			*
	5.	09/17/1991	5,049,389	Radhakrishnun			
	6.	12/27/1994	5,376,386	Ganderton			
-	7.	02/14/1995	5,388,574	Ingebrethsen			
	8.	08/13/1996	5,544,646	Lloyd et al.			
	9.	12/09/1997	5,694,919	Rubsamen et al.			
	10.	04/07/1998	5,735,263	Rubsamen et al.			
	11.	04/14/1998	5,738,865	Baichwal et al.			
	12.	06/02/1998	5,758,637	Ivri et al.			
	13.	06/29/1999	5,915,378	Lloyd et al.			
	14.	08/10/1999	5,934,272	Lloyd et al.			
	15.	09/28/1999	5,957,124	Lloyd et al.			
·	16.	10/05/1999	5,960,792	Lloyd et al.			
	17.	11/30/1999	5,993,805	Sutton et al.			
	18.	03/28/2000	6,041,777	Faithfull et al.			
	19.	04/18/2000	6,051,566	Bianco			
	20.	08/01/2000	6,095,153	Kessler et al.			
	21.	08/15/2000	6,102,036	Slutsky et al.			
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands			
	24.	01/14/2003	6,506,762	Horvath et al.			
	25.	02/04/2003	6,514,482	Bartus et al.			
	26.	07/15/2003	6,591,839	Meyer et al.			

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449			Docket Number: 0023.03CON Application Number: 10/813,722			r: 10/813,722				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant: Joshua D. RABINOWITZ et al.				-			
	(Use several sheets if necessary)			Filing Date: 3/	/31/20	04	Grou	p Art U	nit:	Not Yet Known
		•								
	27:	09/06/2001	US 2001/0020147	Staniforth et al.						
	28.	03/28/2002	US 2002/0037828	Wilson et al.						
	29.	05/16/2002	US 2002/0058009	Bartus et al.						
	30.	07/04/2002	US 2002/0086852	Cantor						
	31.	08/22/2002	US 2002/0112723	Schuster et al.		-				
	32.	11/28/2002	US 2002/0176841	Barker et al.						-
	33.	01/02/2003	US 2003/0004142	Prior et al.						
	34.	02/13/2003	US 2003/0032638	Kim et al.						
REI	LAT	ED ALEXZA M	OLECULAR DELIV	ERY CORPORA	TIOI	N PAT	ENT :	DOC	UM	ENTS
35		08/04/2003	10/633,876	Hale et al.						
36	5.	08/04/2003	10/633,877	Hale et al.						
37	7.	12/30/2003	10/749,537	Rabinowitz et al.						
38	3.	12/30/2003	10/749,539	Rabinowitz et al.						
39).	01/27/2004	10/766,149	Rabinowitz et al.	• • • • • • • • • • • • • • • • • • • •					
40).	01/27/2004	10/766,279	Rabinowitz et al.						
41		01/27/2004	10/766,566	Rabinowitz et al.	··					
42	2	01/27/2004	10/766,574	Rabinowitz et al.						
43).	01/27/2004	10/766,634	Rabinowitz et al.						
44	l.	01/27/2004	10/766,647	Rabinowitz et al.						
45	i.	01/28/2004	10/767,115	Rabinowitz et al.						
46	5.	01/29/2004	10/768,205	Rabinowitz et al.						
. 47	<i>'</i> .	01/29/2004	10/768,220	Rabinowitz et al.			- I			
48	3.	01/29/2004	10/768,281	Rabinowitz et al.						
49).	01/29/2004	10/768,293	Rabinowitz et al.			•			
50).	01/30/2004	10/769,046	Rabinowitz et al.						
51		01/30/2004	10/769,051	Rabinowitz et al.						
52	2.	01/29/2004	10/769,157	Rabinowitz et al.						
53		01/29/2004	10/769,197	Rabinowitz et al.						
54		02/09/2004	10/775,583	Rabinowitz et al.	· · · · ·					
55		02/09/2004	10/775,586	Rabinowitz et al.						
EXAMINE	R:			DATE CONSI	IDER	ED:				
			red, whether or not the citati				ne thro	ough th	e citat	ion if not in

Form PTO-1449			Docket Number: 0023.03CON Application Number: 10/813,722			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant: Joshua D. RABINOWITZ et al.			
	(Use several sheets if nec	essary)	Filing Date: 3/31/2004	Group Art Unit: Not Yet Known		
		• .				
56.	03/03/2004	10/791,915	Hale et al.			
57.	03/03/2004	10/792,001	Rabinowitz et al.			
58.	03/03/2004	10/792,012	Hale et al.			
59.	03/03/2004	10/792,013	Rabinowitz et al.			
60.	03/03/2004	10/792,096	Hale et al.			
61.	03/03/2004	10/792,239	Hale et al.			
62.	03/31/2004	10/813,721	Rabinowitz et al.			
63.	03/31/2004	10/814,690	Rabinowitz et al.	· ·		
64.	03/31/2004	10/814,998	Rabinowitz et al.			
65.	04/01/2004	10/815,527	Rabinowitz et al.			
66.	04/01/2004	10/816,407	Rabinowitz et al.			
67.	04/01/2004	10/816,492	Rabinowitz et al.			
68.	04/01/2004	10/816,567	Rabinowitz et al.			
69.	08/04/2004	10/912,462	Hale et al.	·		
70.	01/23/2003	US 2003/0015196	Hodges et al.			
71.	04/03/2003	US 2003/0062042	Wensley et al.			
72.	11/13/2003	US 2003/0209240	Hale et al.			
73.	01/02/2003	US 2003/0000518	Rabinowitz et al.			
74.	01/09/2003	US 2003/0005924	Rabinowitz et al.	·		
75.	01/09/2003	US 2003/0005925	Hale et al.			
76.	01/09/2003	US 2003/0007933	Rabinowitz et al.	·		
77.	01/09/2003	US 2003/0007934	Rabinowitz et al.			
78.	01/16/2003	US 2003/0012737	Rabinowitz et al.			
79.	01/16/2003	US 2003/0012738	Rabinowitz et al.			
80.	1/16/2003	US 2003/0012740	Rabinowitz et al.			
81.	01/23/2003	US 2003/0015189	Rabinowitz et al.			
82.	01/23/2003	US 2003/0015190	Rabinowitz et al.			
83.	01/23/2003	US 2003/0017114	Rabinowitz et al.			
84.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
85.	01/23/2003	US 2003/0017116	Rabinowitz et al.			
EXAMINER:			DATE CONSIDERED:			
			ion conforms with MPEP 609. Draw a next communication to applicant.	line through the citation if not in		
PTO/SB/ 08 (2-92)				U.S. DEPARTMENT OF COMMERCE		

Form PTO-1449			Docket Number: 0023.03CON Application Number: 10/813,722			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant:	Joshua D. RAB	INOWITZ et al.	
	(Use several sheets if necessary)			3/31/2004	Group Art Unit:	Not Yet Known
86.	01/23/2003	US 2003/0017117	Rabinowitz et a	1		
87.	01/23/2003	US 2003/0017118	Rabinowitz et a	·····		
88.	01/23/2003	US 2003/0017119	Rabinowitz et a			
89.	01/23/2003	US 2003/0017119	Rabinowitz et a			
90.	1/30/2003	US 2003/0021753	Rabinowitz et a			
91.	01/30/2003	US 2003/0021754	Rabinowitz et a			
92.	01/30/2003	US 2003/0021755	Hale et al.	-		
93.	02/20/2003	US 2003/0021733	Hodges et al.			
94.	05/15/2003	US 2003/0091511	Rabinowitz et a	1		
95.	05/27/2004	US 2004/010148	Hale et al.			
96.	07/31/2003	US 2003/0138382	Rabinowitz			
97.	11/06/2003	US 2003/0206869	Rabinowitz et a	1		
98.	01/15/2004	US 2003/0200809 US 2004/0009128	Rabinowitz et a			
98.	05/20/2004	US 2004/0009128 US 2004/0096402		11.		
	05/27/2004	US 2004/0099269	Hodges et al. Hale et al.			
100.						
101.	06/03/2004	US 2004/0105818	Hale et al.			
102.	06/03/2004	US 2004/0105819	Hale et al.	1		·
103.	07/01/2004	US 2004/0126326	Rabinowitz et a			
104.	07/01/2004	US 2004/0126327	Rabinowitz et a			
105.	07/01/2004	US 2004/0126328	Rabinowitz et a			
106.	07/01/2004	US 2004/0126329	Rabinowitz et a	i		
107.	07/01/2004	US 2004/0127481	Rabinowitz et a			
108.	07/01/2004	US 2004/0127490	Rabinowitz et a			
109.	08/12/2004	US 2004/0156788	Rabinowitz et a			
110.	08/12/2004	US 2004/0156789	Rabinowitz et a			
111.	8/12/2004	US 2004/0156790	Rabinowitz et a			
112.	08/12/2004	US 2004/0156791	Rabinowitz et a	1.		
EXAMINER:			DATE CO	NSIDERED:		
EXAMINER: 1 conformance an	Initial if citation considered. Inclu	red, whether or not the citat de a copy of this form with	ion conforms with M	IPEP 609. Draw a to applicant.	line through the cita	ition if not in

PTO/SB/ 08 (2-92)

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 0023.03CON Application Number: 10/813,722

Applicant: Joshua D. RABINOWITZ et al.

Filing Date: 3/31/2004 Group Art Unit: Not Yet Known

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	113.	03/14/1990	EP 0 358 114	Europe			
	114.	07/03/2001	EP 1 080 720	Europe			
	115.	08/29/2001	EP 0 606 486	Europe			
	116.	04/11/1996	WO 96/09846	WIPO			
	117.	05/09/1996	WO 96/13161	WIPO			
	118.	05/09/1996	WO 96/13290	WIPO			
	119.	05/09/1996	WO 96/13291	WIPO			
	120.	05/09/1996	WO 96/13292	WIPO			
	121.	10/03/1996	WO 96/30068	WIPO			
	122.	08/07/1997	WO 97/27804	WIPO			
	123.	05/28/1998	WO 98/22170	WIPO			
	124.	07/23/1998	WO 98/31346	WIPO			
. ,	125.	08/27/1998	WO 98/36651	WIPO			
	126.	04/08/1999	WO 99/16419	WIPO			
	127.	12/16/1999	WO 99/64094	WIPO			
	128.	01/06/2000	WO 00/00176	WIPO .			· · · · · · · · · · · · · · · · · · ·
	129.	01/06/2000	WO 00/00215	WIPO			
	130.	05/18/2000	WO 00/27363	WIPO			
	131.	05/25/2000	WO 00/29053	WIPO			
	132.	09/17/2000	WO 00/47203	WIPO			
	133.	11/02/2000	WO 00/64940	WIPO		·	
	134.	11/09/2000	WO 00/66084	WIPO			
	135.	11/09/2000	WO 00/66206	WIPO			
	136.	12/21/2000	WO 00/76673	WIPO			
	137.	01/25/2001	WO 01/05459	WIPO			
-	138.	05/10/2001	WO 01/32144	WIPO			
	139.	03/28/2002	WO 02/24158	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) Docket Number: 0023.03CON Application Number: 10/813,722 Applicant: Joshua D. RABINOWITZ et al. Filing Date: 3/31/2004 Group Art Unit: Not Yet Known

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	140.	Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," <i>Annual Surg.</i> 195(6):700-705.
·	141.	Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physiological effects," <i>Psychopharmacology</i> (Berl). 102:443-450.
	142.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.
	143.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.
	144.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," <i>Journal of Applied Physiology</i> 32(5):591-600.
	145.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.
	146.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.
	147.	Gonda,I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, <u>The Lung: Scientific Foundations</u> . Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
	148.	Hatsukami D, et al. (May 1990) "A method for delivery of precise doses of smoked cocaine-base to humans." <i>Pharmacology Biochemistry & Behavior</i> . 36(1):1-7.
	149.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.
	150.	Huizer, H., "Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking." Pharmaceutisch Weekblad Scientific Edition (1987). 9(4):203-211.
	151.	Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.
	152.	Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.
	153.	Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," Journal of Analytical Toxicology 13:158-162.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

					Sheet / of /		
Form PTO-1449		Docket Number: 0023.03CON Application Number: 10/813,			er: 10/813,722		
•	ION DISCLOSURE CITATION AN APPLICATION	Applicant:	Joshua D. RAF	BINOWITZ et al.			
. (1	lse several sheets if necessary)	Filing Date:	3/31/2004	Group Art Unit:	Not Yet Known		
154.	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.	. "Smoked he	roin self-adminis	ration in rhesus	monkeys,"		
155.	Meng, Y. et al. "Inhalation Studies Wi 173:201-224.	Meng, Y. et al. "Inhalation Studies With Drugs of Abuse, " NIDA Research Monograph, (1997) 173:201-224.					
156.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," <i>Drug and Alcohology</i>	Meng, Y., et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure," <i>Drug and Alcohol Dependence</i> . 53:111-120.					
157.	Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "DELIVERY OF BENZODIAZEPINES THROUGH AN INHALATION ROUTE".						
158.	Pankow, J.F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form Through the Action of Gaseous Ammonia," <i>Envron. Sci. Technol.</i> 31:2428-2433.						
159.	Pankow, J. (March 2000). ACS Conference pp. 1-8.	rence-San Fra	ncisco-3/26/00. C	Chemistry of Tob	acco Smoke.		
160.	Seeman, J. et al. (1999). "The Form of Nicotine Acid Salts to Nicotine in the	Nicotine in T Gas Phase, " J	obacco. Thermal Agric. Food Ch	Transfer of Nico em. 47(12):5133-	otine and 5145.		
161.	Sekine, H. and Nakahara, Y. (1987). "Inhalation Efficiency and Pyrolysis Property 32(5):1271-1280.						
162.	Vapotronics, Inc. (1998) located at htt June 5, 2000).	p://www.vapo	tronics.com.au/ba	anner.htm., 11 pa	ges, (visited on		
163.	Ward, M.E. MD, et al. (December1997). "Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System," Clinical Pharmacology & Therapeutics 62(6):596-609.						
164.	Wood, R.W. et al. (1996). "Generation of Stable Test Atmospheres of Cocaine Base and Its Pyrolyzate, Methylecgonidine, and Demonstration of Their Biological Activity." <i>Pharmacology Biochemistry & Behavior</i> . 55(2):237-248.						
					·		

EXAMINER:	,	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.